496913-64-5

Basic information

• Product Name: N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide
• CAS NO: 496913-64-5
• Molecular Weight: 333.414
• Mol File: 496913-64-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide(496913-64-5)
• EPA Substance Registry System: N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide(496913-64-5)

Safety Data

• Hazardous Substances Data: 496913-64-5(Hazardous Substances Data)

Upstream product

• 121-90-4 m-nitrobenzoic acid chloride 
• 95-54-5 1,2-diamino-benzene 
• 15456-62-9 2-(3-nitrophenyl)-1H-benzimidazole 
• 65953-23-3 3-nitro-N-[2-[(3-nitrobenzoyl)amino]phenyl]benzamide 
• 39098-97-0 2-thienylacetic acid chloride 
• 7596-74-9 3-(1H-benz[d]imidazol-2-yl)aniline 

Relevant articles and documents

Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae

Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 μM, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 μM against CWL-029 and 6.3 μM against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.